Use of IntelliCyt’s iQue Screener for high-throughput screening of small molecules, CRISPRs and stem cells
ABOUT THIS WEBINAR
This webinar highlights the use of the iQue Screener for high-throughput screening of stem cells, small molecules and CRISPR functional screening. This webinar, supported by IntelliCyt, is presented by David Sykes, M.D., Ph.D., Researcher from Massachusetts General Hospital and Thibault Jonckheere, CEO and Séverine Giltaire, Senior Scientist from ImmunXperts.
The iQue Screener enables rapid assessment of cells in suspension such as those found on blood and bone marrow and miniaturises the assay format, thus conserving precious samples for further analysis.
CRISPR/Cas9 screen: David Sykes’ presentation discusses data obtained from the iQue Screener in a CRISPR/Cas9 screen and a small molecule screen to gain biological insights into Acute Myeloid Leukemia (AML) and identify new therapies for patients.
Stem Cell Screen: Thibault Jonckheere introduces speaker Séverine Giltaire’s who talks about the ability of the iQue Screener to run a high throughput high content potency screen to evaluate the functionality of stem cells and their role in immunomodulation.
David B. Sykes, MD, PhD
Massachusetts General Hospital
David Sykes completed his undergraduate training in Biochemistry at the University of Alberta in Edmonton, Canada. He entered the Medical Scientist Training Program (M.D., Ph.D.) at the University of California San Diego and carried out his Ph.D. research. David did his internship and residency at the Massachusetts General Hospital. David joined the MGH Cancer Center as an attending in benign hematology. He splits his time between the laboratory (80% research) and clinic (20% direct patient care). He sees patients with all diagnoses with a focus on patients with myeloproliferative disorders. David’s research involves understanding and identifying new treatments for acute myeloid leukemia. He is focused on designing drugs for patients with acute myeloid leukemia that trigger differentiation, or maturation, of the leukemic cells.
Thibault started his career at GDF Suez in the utilities/energy sector by holding several European positions in the financial department and launching the internal consultancy service. After this he joined MaSTherCell, a CMO specialized in cell therapy manufacturing, as Chief Business Officer. In this position he helped grow the company from 10 to over 90 persons working on a high number of different cell therapy products. Thibault joined ImmunXperts with the challenge to continue developing innovative therapies for unmet clinical needs. Thibault holds a Master of Business Engineering from the Solvay Brussels School of Economics and Management.
Séverine Giltaire has several years of experience in research and development. After her PhD in Biomedical and Pharmaceutical Sciences at the University of Namur (2006-2010), she worked 2 years at Quality Assistance as an analyst R&D and gained experience in cellular assays. From 2013 to the beginning of 2015, she successfully managed a scientific research project between the University of Namur and StratiCELL, where she acquired in-depth knowledge in immune T cells culture and activation. She joined ImmunXperts as a Senior Scientist in April 2015.
The iQue Screener platform is an integrated instrument, software and reagent system that enables rapid, high content, multiplexed analysis of cells and beads in suspension.
The iQue Screener platform delivers insights from complex experiments fast. Analysed results from 96-well experiments are ready in as little as 5 minutes. Assay volumes can be reduced to less than 10 µL, so more data can be generated from limited samples and costs dramatically reduced. Cells and secreted proteins can be analysed together in the same well. ForeCyt software supports the entire workflow, from plate mapping through interactive data visualisation and report generation. Combined, the instrumentation and software make it easy to decipher combinatorial experiments.
The IntelliCyt Advantage delivers more of what matters when profiling single cells for functional and phenotypic endpoints: